This e-learning course and associated podcasts review the topic of radiopharmaceuticals and their use in metastatic castration-resistant prostate cancer. International experts in the field of GU Oncology and Nuclear Medicine provide an overview of radiopharmaceuticals used in prostate cancer.

The discussion covers:

  • their mechanism of action
  • data from key registration trials
  • real-world evidence
  • treatment sequencing considerations
  • general radiation safety
  • a review of ongoing trials looking at these drugs in combination with other prostate cancer treatments

This e-learning comprises information from two podcast episodes:

  • Episode 1 focuses primarily on radium-223
  • Episode 2 focuses on theranostics with PSMA-targeted radiopharmaceuticals

 

This course, comprising of episodes 1 and 2, has been accredited by EACCME® for 1 ECMEC® (as detailed within the Introduction and Objectives below)